Predisposition to hereditary breast cancer has been attributed in part to inherited mutations in the BRCA2 gene. The large protein it encodes is still poorly characterized with respect to functions. We have previously shown that BRCA2 has transcriptional activation potential conferred by its amino-terminal third exon. Here, we show that BRCA2 interacts with a transcriptional co-activator protein, P/CAF, which possesses histone acetyltransferase activity. The interaction with P/CAF is demonstrated in vitro as well as in vivo and is shown to be mediated by residues 290 ± 453 of BRCA2. Consistent with the binding to an acetyltransferase, BRCA2 is shown to associate with acetyltransferase activity in nuclear extracts. Contrary to a recent report, we ®nd no evidence in support of an intrinsic HAT activity in BRCA2 amino-terminus. Our results further substantiate the notion that BRCA2 has transcriptional activation function and suggest that one mechanism by which BRCA2 regulates transcription may be through the recruitment of histone-modifying activity of the P/CAF co-activator.
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Keywords: BRCA2; P/CAF; histone acetyltransferase Mutations within the BRCA2 gene account for approximately 45% of families with inherited breast cancers (Wooster et al., 1995) . BRCA2 is composed of 27 exons and encodes a very large protein of 3418 amino acids (Tavtigian et al., 1996) . Initially, the cloning of the BRCA2 gene did not provide much insight into its cellular function(s) because the sequence of its gene product showed no strong homologies to known proteins. However, recent reports have now led to the proposal that BRCA2 has a role in DNA repair. BRCA2-de®cient mouse embryos were shown to be highly sensitive to g-irradiation (Sharan et al., 1997) . In addition, BRCA2 was demonstrated to physically interact with the Rad51 protein, the eukaryotic equivalent of bacterial Rec A that is involved in DNA repair and recombination. This interaction occurs through binding sites within exon 11 (Sharan et al., 1997; Wong et al., 1998; Chen et al., 1998) . Recently, the generation of viable mutant mice with truncated BRCA2 alleles further substantiated the notion that BRCA2 is involved in DNA repair (Patel et al., 1998) .
We have previously shown that exon 3 at the aminoterminus of BRCA2 when linked to GAL4 DNAbinding domain has the ability to activate transcription (Milner et al., 1997) . Thus, beside its above-mentioned role in DNA repair, our ®nding suggest also a role of BRCA2 in the regulation of gene expression. Importantly, we ®nd that cancer predisposing germline mutations disrupt the activation potential of BRCA2, suggesting that compromising this activity might be an important step in the generation of familial breast cancer. This notion is further supported by the recent identi®cation of an in-frame deletion of BRCA2 exon 3, as the disease-causing mutation in a breast cancer family (Nordling et al., 1998) .
Histone acetylation is a characteristic feature of transcriptionally active chromatin and is considered as a major source to overcome chromatin-associated gene repression (review in Struhl, 1998; Davie, 1998) . Recent ®ndings indicate that the histone acetyltransferases (HATs) responsible for acetylation of histones consist of already known transcriptional cofactors, such as GCN5 , CBP/p300 Ogryzko et al., 1996) , P/CAF , TAFII250 (Mizzen et al., 1996) and SRC-1 (Spencer et al., 1997) . These results suggest that chromatin remodelling by cofactors, through histone acetylation, can regulate transcription.
In the present study, we show that (1) BRCA2 speci®cally interacts with the histone acetyltransferase P/CAF; (2) this interaction requires residues 290 ± 453 in the N-terminus of BRCA2, and (3) BRCA2 Nterminus associates with HAT activity when bound to P/CAF but lacks intrinsic HAT activity. These results suggest that one mechanism by which BRCA2 participates in transcriptional regulation is through its association with P/CAF histone acetyltransferase.
Given the fact that BRCA2 may function to regulate transcription, we set out to establish whether BRCA2 interacts with known co-activator proteins. By means of an in vitro GST-pull-down assay, we found that residues 1 ± 658 of BRCA2, encompassing the exon 3 activation domain, linked to GST binds to in vitro translated and radiolabelled full-length P/CAF ( Figure  1b , lane 3). This binding was as ecient as the interaction between E1A and P/CAF (lane 6; Reid et al., 1998) and was speci®c, since P/CAF failed to bind to the control GST alone (lane 2). Deletion analysis indicates that residues encompassing the BRCA2 activation domain did not mediate the interaction with P/CAF since GST 18 ± 141 (lane 7) and GST 60 ± 105 (lane 9) did not bind P/CAF. However, further truncations indicate that sequences lying downstream of exon 3 are responsible for the association with 35 S-labelled P/CAF. As shown in Figure 1b , radiolabelled P/CAF interacts with GST BRCA2 223 ± 453 (lane 4) and 290 ± 453 (lane 5) but not with GST 98 ± 223 (lane 8). Thus, the region of BRCA2 extending from residues 290 ± 453 was found to be sucient for interaction with P/CAF. This region is located within exon 10 of BRCA2 (see Figure 1a) , and represents a domain highly conserved between mouse and human.
Having shown an interaction in vitro between BRCA2 and P/CAF, we next sought to con®rm this interaction in vivo. Since antibodies which immunoprecipitate BRCA2 or P/CAF are unavailable, we performed coimmunoprecipitation experiments in 293T cells, in which a Flag-tagged version of P/CAF (F-P/CAF) was transfected along with Ha-tagged version of BRCA2 1 ± 1963 (Ha-BRCA2 1 ± 1963). To ®rst ensure that the BRCA2 construct was expressed properly, cells were transfected with Ha-BRCA2 1 ± 1963 and immunoprecipitate with anti-Ha antibody followed by Western blot using that same antibody. Figure 2a (lane 1) indicates that Ha-BRCA2 1 ± 1963 gives rise to the expected product. When F-PCAF and Ha-BRCA2 1 ± 1963 were cotransfected in 293T cells, an interaction was detected after precipitation with anti-Ha antibody followed by Western blot analysis using anti-Flag antibody (Figure 2b , lane 1). This interaction was speci®c as demonstrated by the following controls: no precipitate was detected after transfection of either Ha-BRCA2 or F-P/CAF alone (lanes 2 and 3, respectively), or after substitution of the Ha antibody with control antisera (either anti-JNK1 or Below are shown enlarged exon 3 activation domain (residues 18 ± 105; Milner et al., 1997) and exon 10 with the P/CAF interaction domain (residues 290 ± 453) identi®ed in this study. Numbers indicated amino acids position from the N-terminus. Also shown is a schematic representation of the GST fusion BRCA2 fragments tested for interaction with P/CAF. On the right is summarized the results presented in (b), which shows the ability of the BRCA2 constructs to interact with P/CAF in pulldowns (+ indicates interaction, 7 indicates no interaction). (b) In vitro-translated and 35 S-labelled full-length P/CAF was incubated with equivalent amounts of bacterially expressed GST (lane 2) or GST fusions of BRCA2 (lanes 3 ± 5 and 7 ± 9) or, as a positive control, GST E1A (amino-acids 1 ± 90; lane 6). The reactions were subjected to GST pull-down assay. The pull-downs were performed essentially as described previously (Hagemeier et al., 1993) . The bound P/CAF is indicated by an arrow at left. Input (lane 1) represents 10% of the radiolabelled protein used in the binding assays . Forty-eight hours after transfection, cells were lysed in 500 ml of IPH buer . Immunoprecipitation of whole cell extracts was followed by Western blot analysis using anti-Ha antibody (3F10, Boehringer; lanes 1 and 2). Immunoreactive bands were visualized using an ECL kit (Amersham). Ha-BRCA2 1 ± 1963 is indicated on the left by an arrow. (b) 293T were transfected with 10 mg of Flag-tagged pCX-P/CAF ; F-P/CAF, lanes 1 and 3 ± 6) and 30 mg of either pCMV-Ha-BRCA2 1 ± 1963 (lanes 1, 2, 4 and 5) or empty CMV vector (7, lane 3) or pCMV-Ha-BRCA2 60 ± 105 (lane 6). Immunoprecipitation was then performed using either anti-Ha antibody (lanes 1 ± 3 and 6) or control antisera (anti-JNK1, F-3, Santa Cruz, lane 4; anti-myc, 9E10, Boehringer, lane 5). After separation of immunocomplexes by SDS ± PAGE, Western blotting was performed with anti-Flag antibody (M2, Kodak). Lane 1: coimmunoprecipitation of Ha-BRCA2 1 ± 1963 with F-P/CAF (the position of F-P/CAF is shown by an arrow on the left). Lanes 2 ± 6: negative controls to assess the speci®city of P/CAF precipitate detected in lane 1 BRCA2 interacts with P/CAF acetyltransferase F Fuks et al anti-myc, lanes 4 and 5 respectively). The Ha-speci®c antibody did not immunopurify Ha-BRCA2 60 ± 105 (Figure 2b , lane 6), consistent with the ®nding that GST BRCA2 60 ± 105 did not bind in vitro translated P/CAF (see Figure 1b , lane 9). Taken together, our data indicate that BRCA2 speci®cally interacts with P/ CAF both in vitro and in vivo, and that this interaction occurs via residues within exon 10 of BRCA2. The human P/CAF protein possesses intrinsic histone acetyltransferase activity . Therefore, we asked whether BRCA2 carries histone acetylase activity when bound to P/CAF. To address this question, we performed immunoprecipitation-HAT (IP-HAT) assays , in which immuno-complexes are assayed by liquid scintillation counting for their ability to incorporate (Figure 3, lane 3) . This might be due to the fact that 293T cells contain very low level of endogenous P/CAF (data not shown).
When exogenous P/CAF (F-P/CAF) was introduced into 293T together with Ha-BRCA2 1 ± 1963 and followed by immunoprecipitation with anti-Ha antibody, HAT activity was readily detectable (Figure 3 , lane 4). In contrast, control transfection of F-P/CAF alone resulted in only background activity (Figure 3 , lane 2). The HAT activity precipitated by Ha-BRCA2 1 ± 1963 through an interaction with P/CAF (lane 4) is comparable to the HAT activity precipitated by an Ha-CBP fusion (lane 8). Importantly, given the fact that 293T cells have low level of endogenous P/CAF and that BRCA2-bound HAT activity was strictly dependent upon the introduction of exogenous P/CAF into 293T cells, we inferred that the BRCA2-associated HAT activity was a result of BRCA2 binding P/CAF rather than an intrinsic property of BRCA2.
Consistent with the P/CAF binding presented in Figure 1b , a region of BRCA2 which does not bind P/ CAF (Ha-BRCA2 18 ± 141) is unable to associate with acetyltransferase activity (lane 7) whereas a domain encompassing the P/CAF-binding site (Ha-BRCA2 18 ± 450) can do so (lane 6). Collectively, these data indicate that the ability of BRCA2 N-terminus to contact histone acetylase activity correlated with its binding to P/CAF acetyltransferase.
During the preparation of this manuscript, Siddique et al. (1998) reported that the BRCA2 is itself a histone acetyltransferase. These authors described that this activity maps to an N-terminal region of BRCA2 Figure 3 BRCA2 amino-terminus binds HAT activity in a P/ CAF-dependent manner. 293T cells were transiently tranfected with 30 mg of the indicated pCMV-Ha-BRCA2 expression plasmids and/or 10 mg of pCX-P/CAF (expressing Flag-tagged full-length P/CAF, Yang et al., 1996 ; F-P/CAF) or 10 mg of RSV-CBP (expressing Ha-tagged full-length CBP; a gift of R Goodman). Forty-eight hours after transfection, immunoprecipitation using whole cell extracts were performed with anti-Ha antibody (3F10, Boehringer). After extensive washing, the immune complexes were tested for their ability to acetylate free histones in the liquid HAT assay. IP-HAT assays were performed as described previously . Ha-CBP was used as a positive control. Note that no signi®cant HAT activity is observed with Ha-BRCA2 1 ± 1963 and 18 ± 450 unless F-P/CAF is cotransfected Figure 4 BRCA2 amino-terminus is devoid of intrinsic HAT activity. BRCA2 amino-terminal fragments (containing either residues 18 ± 141 or 1 ± 658; see Figure 1a for a schematic representation) were expressed in E. coli as GST fusions and subsequently puri®ed. The GST BRCA2 fusions were tested for HAT activity using the standard liquid HAT assay . Bacterially expressed GST alone was used as negative control for HAT activity. GST P/CAF served as positive control. Increasing amounts of the GST fusions (either 50 ng or 500 ng) were used in the liquid HAT assay BRCA2 interacts with P/CAF acetyltransferase F Fuks et al spanning residues 1 ± 500. As described below, we have not found any evidence in support of an intrinsic HAT activity in BRCA2 amino-terminus. Our conditions are similar to those used by Siddique et al. (1998) , in that bacterially expressed GST fusion proteins were used in a liquid HAT assay. In our hands, GST fusions vary up to ®vefold in HAT activity as compared to the background level represented by GST alone. In addition, we ®nd typically that known HATs show HAT activity 40 ± 60-fold above background, which gives a clear indication that a protein has intrinsic HAT activity. As shown in Figure 4 , when we used GST-BRCA2 18 ± 141 and 1 ± 658 in the liquid HAT assay, no signi®cant HAT activity above background was detected. Furthermore, these BRCA2 fusion proteins were clearly negative for HAT activity as compared to the positive control GST P/CAF ( Figure  4) . It is worth noting that similar amounts of BRCA2 and P/CAF proteins were used to monitor HAT activity. We have also tested the precise construct used by Siddique et al. (1998) , i.e. GST fused to amino acids 1 ± 500 of BRCA2. We ®nd that this construct is also negative for HAT activity (data not shown).
Thus, the above-mentioned data are clearly dierent from results reported previously. Although the precise reason for this discrepancy remains unclear, it is noteworthy that we ®nd the presence of contaminating histone acetylase activity in some crude histones preparations (unpublished observations). Such contamination might be responsible for the previously reported low level of HAT activity associated with BRCA2 amino-terminus. Although the data presented here indicate that the amino-terminal half of BRCA2 lacks intrinsic histone acteyltransferase activity, we cannot rule out at this point the possibility that the carboxy-terminal half of BRCA2 possesses such intrinsic enzymatic activity.
In summary, we have shown that BRCA2 interacts with the histone acetyltransferase P/CAF and displays associated HAT activity when bound to it. Following our previous demonstration that BRCA2 exon 3 is an activation domain, the present data further support the notion that BRCA2 is involved in transcriptional regulation. The mechanism by which BRCA2 modulates transcription may be, at least partly, through the recruitment of histone-modifying activity of P/CAF.
